Formoterol
- Generic Name
- Formoterol
- Brand Names
- Bevespi, Breyna, Breztri, Duaklir, Duaklir Genuair, Dulera, Foradil, Oxeze, Perforomist, Symbicort, Zenhale
- Drug Type
- Small Molecule
- Chemical Formula
- C19H24N2O4
- CAS Number
- 73573-87-2
- Unique Ingredient Identifier
- 5ZZ84GCW8B
- Background
Formoterol is an inhaled beta-agonist used in the management of COPD and asthma that was first approved for use in the United States in 2001. It acts on bronchial smooth muscle to dilate and relax airways, and is administered as a racemic mixture of its active (R;R)- and inactive (S;S)-enantiomers. A major clinical advantage of formoterol over other inhaled ...
- Indication
Formoterol is indicated in various formulations for the treatment of asthma and COPD. For the treatment of COPD, formoterol is available as a single-entity inhalation solution, in combination with the long-acting muscarinic antagonists (LAMAs) aclidinium and glycopyrronium, and in combination with the corticosteroid budesonide. For the treatment of asthma, f...
- Associated Conditions
- Asthma, Bronchial Asthma, Bronchoconstriction, Chronic Obstructive Pulmonary Disease (COPD), Exercise-Induced Bronchospasm, Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
- Associated Therapies
- Maintenance therapy
Study to Assess the Efficacy and Safety of Omalizumab Treatment on ICS Reduction for Severe IgE-mediated Asthma
- Conditions
- Interventions
- First Posted Date
- 2013-07-31
- Last Posted Date
- 2019-07-02
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 112
- Registration Number
- NCT01912872
- Locations
- 🇲🇽
Novartis Investigative Site, Mérida, Yucatán, Mexico
Effects of Particle Size in Small Airways Dysfunction
- First Posted Date
- 2013-07-04
- Last Posted Date
- 2019-04-12
- Lead Sponsor
- University of Dundee
- Target Recruit Count
- 17
- Registration Number
- NCT01892787
- Locations
- 🇬🇧
Brian Lipworth, Dundee, United Kingdom
Polymorphism of beta2-adrenoceptor and Regular Use of Formoterol in Asthma
- First Posted Date
- 2013-02-08
- Last Posted Date
- 2013-02-08
- Lead Sponsor
- Catholic University, Italy
- Target Recruit Count
- 30
- Registration Number
- NCT01786616
- Locations
- 🇮🇹
Catholic University, Pneumology Unit, Rome, Italy
LIPS-B: Lung Injury Prevention Study With Budesonide and Beta
- Conditions
- Interventions
- First Posted Date
- 2013-02-05
- Last Posted Date
- 2016-09-05
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 61
- Registration Number
- NCT01783821
- Locations
- 🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸Stanford University, Stanford, California, United States
🇺🇸University of Arizona, Tucson, Arizona, United States
The Effects of Atorvastatin Treatment in COPD Patients
- First Posted Date
- 2012-12-12
- Last Posted Date
- 2013-04-23
- Lead Sponsor
- Medical University of Bialystok
- Target Recruit Count
- 18
- Registration Number
- NCT01748279
- Locations
- 🇵🇱
Department of Lung Diseases and Tuberculosis, Medical University of Bialystok, Bialystok, Poland
Effects of Symbicort on the Ventilatory Kinematics
- Conditions
- Interventions
- First Posted Date
- 2012-10-24
- Last Posted Date
- 2016-09-02
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 9
- Registration Number
- NCT01712854
- Locations
- 🇺🇸
Columbia University Medical Center, New York, New York, United States
The Effect of QVA149 on Health Related Quality of Life in Patients With Chronic Obstructive Pulmonary Disease (COPD)
- First Posted Date
- 2012-04-10
- Last Posted Date
- 2014-05-22
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 934
- Registration Number
- NCT01574651
- Locations
- 🇩🇪
Novartis Investigative Site, Zerbst, Germany
Pharmacokinetic, Safety and Tolerability Study of Aclidinium/Formoterol Fixed Dose Combination and Formoterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- Interventions
- First Posted Date
- 2012-03-13
- Last Posted Date
- 2017-02-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 24
- Registration Number
- NCT01551888
- Locations
- 🇺🇸
Forest Investigative Site 001, Spartanburg, South Carolina, United States
Pharmacokinetic Pilot Study on Budesonide/Formoterol
- Conditions
- Interventions
- First Posted Date
- 2011-10-24
- Last Posted Date
- 2012-02-03
- Lead Sponsor
- Orion Corporation, Orion Pharma
- Target Recruit Count
- 17
- Registration Number
- NCT01457716
- Locations
- 🇩🇪
Parexel International GmbH, Berlin, Germany
Steroids, Azithromycin, Montelukast, and Symbicort (SAMS) for Viral Respiratory Tract Infection Post Allotransplant
- First Posted Date
- 2011-09-12
- Last Posted Date
- 2021-10-20
- Lead Sponsor
- Maisonneuve-Rosemont Hospital
- Target Recruit Count
- 12
- Registration Number
- NCT01432080
- Locations
- 🇨🇦
Maisonneuve-Rosemont Hospital (Hôpital Maisonneuve-Rosemont), Montreal, Quebec, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.